Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Gilead Sciences, Inc. < Previous 1 2 3 4 5 6 7 8 9 Next > Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection July 28, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) July 22, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19 July 22, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic July 21, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity July 20, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir) July 19, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022 July 12, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel July 12, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma June 28, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor June 27, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases June 27, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV June 24, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks June 23, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022 June 21, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC June 06, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma June 04, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma (LBCL) June 04, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients June 04, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity June 03, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing June 02, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report May 19, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting May 17, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV May 16, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation May 02, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces First Quarter 2022 Financial Results April 28, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conferences April 26, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19 April 25, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19 April 24, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland April 19, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022 April 14, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.